---

---

published : This month    tags : Trial   

save search

---

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Published: 2024-04-19 (Crawled : 20:00) - globenewswire.com
HEPA | News | $2.11 -0.09% -0.09% 73K |

Health Technology

| Email alert Add to watchlist
pharmaceuticals trial

---

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Published: 2024-04-19 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M |

Health Technology

| -13.44% | O: -15.41% H: 6.2% C: 2.33%
ocu410 armada trial therapy

---

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K |

n/a

| -22.34% | O: -7.45% H: 0.0% C: 0.0%
hepatitis vaccine license granted biopharma virus trial

---

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $17.65 -2.4% 4K |

Health Technology

| 2.02% | O: -0.87% H: 3.58% C: -2.86%
nephropathy congress world nefecon trial therapeutics

---

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.89 1.03% 1.02% 250K |

Health Technology

| 40.08% | O: 5.41% H: 41.06% C: 29.66%
bb-301 first positive biopharma for trial opmd study

---

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K |

Finance

| 1.55% | O: 0.78% H: 0.0% C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living

---

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
BPTH | News 0 d | $4.17 -0.71% -0.96% 2.1M |

Health Technology

| 37.06% | O: 72.84% H: 41.77% C: -22.37%
bp1002 leukemia trial

---

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | $2.46 -1.21% -1.22% 21K |

Health Technology

| 0.84% | O: 4.43% H: 0.0% C: 0.0%
dm199 first stroke treatment for trial therapeutics

---

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
AFMD | $5.15 1.58% 1.55% 64K |

Health Technology

| -4.1% | O: -2.42% H: 0.0% C: 0.0%
allonk first candidate lupus cell trial therapy

---

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M |

Health Technology

| -0.6% | O: 1.22% H: 0.21% C: -0.34%
vent-02 trial therapeutics results

---

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.25 2.27% 2.22% 90K |

Health Technology

| -3.43% | O: -6.87% H: 0.0% C: 0.0%
tacti-004 lung positive cancer cell for trial

---

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Published: 2024-04-17 (Crawled : 12:00) - prnewswire.com
NRBO | $3.325 -3.34% -3.46% 21K |

Health Technology

| -0.88% | O: 8.53% H: 0.0% C: -6.23%
da-1726 obesity first treatment pharmaceuticals for trial

---

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K |

Manufacturing

| 5.9% | O: 0.25% H: 0.0% C: 0.0%
evx-01 first vaccine cancer trial

---

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
CTSO | $0.8026 0.2% 0.2% 46K |

Health Technology

| -2.2% | O: -0.99% H: 0.0% C: 0.0%
association presentation for meeting trial results

---

BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| 0.63% | O: 0.12% H: 0.51% C: 0.51%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| 0.94% | O: 1.05% H: 0.0% C: 0.0%
management company cell nurown trial therapeutics

---

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLPT | $5.35 -0.74% -0.75% 130K |

Health Technology

| Email alert Add to watchlist
avb-101 first dementia for trial

---

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 15:00) - hancockjaffe.com
NVNO | $4.65 -2.72% -2.8% 71K |

Manufacturing

| -6.1% | O: -1.22% H: 0.0% C: -2.06%
venovalve symposium topline medical trial

---

New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.65 -2.72% -2.8% 71K |

Manufacturing

| -6.1% | O: -1.22% H: 0.0% C: -2.06%
symposium topline medical trial

---

QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
GIA | $1.08 237.96% 1.4K |

| Email alert Add to watchlist
breast technology trial imaging

---

PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
PTCHF | $2.78 19.97% 560 |

n/a

| Email alert Add to watchlist
lyt-100 fibrosis trial

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---